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AbsTrACT
background/aims To investigate the yearly change 
of real- world outcomes for best corrected visual acuity 
(BCVA) after 2- year clinical intervention for treatment- 
naïve diabetic macular oedema (DMO).
Methods Retrospective analysis of aggregated, 
longitudinal medical records obtained from 27 
retina specialised institutions in Japan from Survey 
of Treatment for DMO database. A total of 2049 
treatment- naïve centre involving DMO eyes of which 
the initial intervention started between 2010 and 
2015, and had been followed for 2 years, were 
eligible. As interventions, antivascular endothelial 
growth factor (VEGF) agents, local corticosteroids, 
macular photocoagulation and vitrectomy were 
defined. In each eye, baseline and final BCVA, 
the number of each intervention for 2 years was 
extracted. Each eye was classified by starting year of 
interventional treatment.
results Although baseline BCVA did not change by 
year, 2- year improvement of BCVA had been increased, 
and reached to +6.5 letters in the latest term. There is 
little difference among starting year about proportions 
of eyes which BCVA gained >15 letters, in contrast to 
those which lost >15 letters were decreased by year. 
The proportion of eyes receiving anti- VEGF therapy 
was dramatically increased, while those receiving 
the other therapies were gradually decreased. The 
proportion of eyes which maintained socially good 
vision of BCVA>20/40 has been increased and reached 
to 59.0% in the latest term.
Conclusion For recent years, treatment patterns for 
DMO have been gradually but certainly changed; as 
a result, better visual gain, suppression of worsened 
eyes and better final BCVA have been obtained. Anti- 
VEGF therapy has become the first- line therapy and its 
injection frequency has been increasing.
InTroduCTIon
Diabetic macular oedema (DMO) is a leading 
cause of blindness in working age people, with an 
estimated global prevalence of 21 million individ-
uals.1 Although DMO, a frequent microvascular 
complication, is characterised by vascular leakage 
and accumulation of extracellular fluid in the 
macula because of breakdown of the blood–retinal 
barrier,2 the pathophysiology of DMO is complex 
and involves multiple pathways that lead to central 
thickening and, if untreated, visual loss.3 Thus, 
several therapeutic modalities have been proposed 
for the treatment of DMO. Historically, laser 
photocoagulation was established as the standard 
treatment for DMO in the 1980s,4 and vitrectomy 
was introduced in 1990s,5 followed by medical 
treatment with intravitreal6 or posterior subtenon7 
injection of triamcinolone acetonide (TA) in 2000s. 
In recent years, the treatment of DMO has changed 
greatly with the advent of antivascular endothelial 
growth factor (VEGF) agents.8 Large clinical studies 
demonstrate that the effects of anti- VEGF therapy 
on DMO are functionally and anatomically supe-
rior to those of the other therapies.9–13 Although 
continuous anti- VEGF injections over 2 years 
improved visual acuity in patients with DMO from 
8 to 12 letters14 15 which bring better visual prog-
nosis than the other treatments, a third of patients 
have an incomplete response to anti- VEGF therapy 
and thus a multimodal approach has the potential 
to treat complex aspects of DMO.16 In the ‘real- 
world’ clinical situations, anti- VEGF agents and 
other therapies with or without anti- VEGF agents 
are still being conducted.
The database, Survey of Treatment for DMO 
(STREAT- DMO), consisted of more than 2000 
medical records from a demographically and 
geographically diverse patient sample in Japan, 
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Table 1 Patient demographics at initial treatment
overall 2010–2012 2011–2013 2012–2014 2013–2015 2014–2016 2015–2017
P value for 
AnoVA
P value for 
trend test
Number of eyes 2049 136 285 365 551 468 244 – –
Number of patients 1552 105 229 258 405 364 191 – –
Mean age (years)* 63.5±10.8 64.8±10.7 64.0±10.6 63.3±11.1 62.3±11.4 64.6±10.3 63.0±9.5 0.033 0.547
Sex (male/female) 989/563 63/42 139/90 166/92 252/153 247/117 122/69 0.458 0.145















HbA1c (%)* 7.7±1.8 7.5±1.5 7.6±1.8 7.6±1.7 7.9±2.0 7.6±1.6 7.7±1.8 0.170 0.425

































*Data are provided as mean±SD.
†Data are provided as median with range.
ANOVA, analysis of variance; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA1c, glycohaemoglobin.
centre involving DMO without any previous interventions, and 
started initial treatment for centre involving DMO between 
January 2010 and December 2015, and had been followed 
for 2 years.17 Within this period, anti- VEGF agents of ranibi-
zumab (February 2014) and aflibercept (November 2014) were 
approved to DMO in Japan. Thus, treatment patterns for DMO 
and its visual prognosis must be changed by year, but there were 
no reports about fluctuation of visual prognosis and intervention 
required for centre- involving DME by year to year.
In this study, to use this database, fluctuation of treatment 
patterns and 2- year visual prognosis were analysed and compared 
among starting year of intervention for DMO.
MeThods
In this study, all data were obtained from STREAT- DMO data-
base in Japan, previously described.17 In brief, this retrospective 
observational study included all eligible patients who received 
a diagnosis of treatment- naïve centre involving DMO, started 
initial treatment between January 2010 and December 2015, 
and were followed for 2 years (22–26 months). Baseline clinical 
data obtained from the medical record of each patient included 
the age, gender, duration of diabetes, glycohaemoglobin and 
estimated glomerular filtration rate calculated from the creat-
inine level at initiation of treatment. The best corrected visual 
acuity (BCVA) determined with a decimal chart and the central 
macular thickness (CMT) measured by optical coherence tomog-
raphy (OCT) at the initial and final visits were also extracted 
from the database. CMT in each eye at baseline and final visit 
was obtained by the same OCT device. Interventions for each 
eye during the 2- year period were determined. Centre involving 
DMO was diagnosed at each institution, and the timing of treat-
ment was decided by each attending physician.
In Japan, ranibizumab was approved for DMO in February 
2014, and aflibercept in November 2014. Bevacizumab was 
off label used before the approval of these two drugs and the 
treatment regimen of all anti- VEGF agents was decided by each 
physician. Treatment for DMO was classified as follows: (1) 
anti- VEGF agents (intravitreal bevacizumab (IVB), ranibizumab 
(IVR) or aflibercept (IVA)), (2) local corticosteroid (TA) therapy 
(intravitreal TA (IVTA) or subtenon TA (STTA)), (3) laser photo-
coagulation of the macular region and (4) vitrectomy. If cataract 
surgery was performed or laser photocoagulation outside the 
macular region was done to prevent retinal ischaemia during the 
2- year period, this was also recorded because it could influence 
the visual prognosis.
The study was registered with the University Hospital 
Medical Information Network individual case data repository 
(UMIN#23160).
Clinical evaluation
To facilitate data analysis, decimal BCVA data were converted 
to the logarithm of the minimum angle of resolution (logMAR) 
values or ETDRS equivalent letter scores, as appropriate.18 
Improvement of BCVA was determined by subtracting the final 
BCVA from the baseline BCVA. If BCVA increased by more than 
0.3 logMAR (15 letters), this was defined as ‘improved’, while 
deterioration by more than 0.3 logMAR (15 letters) was defined 
as ‘worsened’. The proportion of eyes with each prognosis was 
calculated.
The goal of treating DMO is to keep useful BCVA, so the 
percentage of eyes with a final BCVA better than 0.3 logMAR 
(20/40 or more on a Snellen chart) was also calculated, since this 
represents socially useful vision and is defined as ‘good’ VA; in 
contrast, BCVA worse than 0.3 logMAR (20/40 or less on the 
Snellen chart) was defined as ‘poor’ VA.
Alterations of treatment patterns and visual prognosis by 
starting year of intervention
To investigate the alterations of treatment patterns and visual 
prognosis, eligible eyes were classified by the starting year 
of interventional treatment. Total number, proportions of 
each intervention and clinical parameters in each group were 
extracted. Proportions of each anti- VEGF agents (IVB, IVR and 
IVA), and injection method of local corticosteroid (IVTA and 
STTA) were also calculated in each group.
statistics
Results are presented as the mean±SD or median with IQR. 
One- way analysis of variance (ANOVA) was used to compare 
normally distributed continuous variables, while the Kruskal- 
Wallis H- test was employed to evaluate skewed variables. The 
χ2 test was used to compare nominal scale variables. Treatment 
period comparisons were carried out with the paired t- test. 
Trend test for continuous term was analysed using linear regres-
sion model and Cochran- Armitage tests for trend, respectively. 
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Table 2 Visual and anatomical outcomes for 2 years
overall 2010–2012 2011–2013 2012–2014 2013–2015 2014–2016 2015–2017
P value for 
AnoVA




0.44±0.37 0.46±0.33 0.51±0.41 0.44±0.35 0.44±0.36 0.40±0.35 0.43±0.38 0.003 0.002
Good/poor (eyes) 735/1314 38/98 82/203 129/236 195/356 198/270 93/151 0.002 <0.001
Final BCVA (logMAR) 0.40±0.42 0.49±0.39 0.45±0.44 0.44±0.43 0.41±0.48 0.33±0.35 0.30±0.36 <0.001 <0.001
Good/poor (eyes) 949/1100 48/88 119/166 140/225 256/295 242/226 144/100 <0.001 <0.001
Difference of BCVA −0.04±0.40 0.03±0.41 −0.06±0.38 0.00±0.43 −0.03±0.45 −0.07±0.34 −0.13±0.31 <0.001 <0.001
P value <0.001 0.3527 0.0055 0.9523 0.1107 <0.001 <0.001 – –
95% CI (logMAR) −0.0622 to −0.0278 −0.0372 to 0.1035 −0.1078 to −0.0188 −0.0427 to 0.0454 −0.0680 to 0.0070 −0.0978 to −0.0361 −0.1658 to −0.0884 – –
Baseline CMT (μm) 443.8±154.8 435.7±165.8 447.3±155.9 456.1±158.1 446.1±161.1 441.1±151.5 425.9±131.8 0.279 0.180
Final CMT (μm) 335.6±139.6 347.9±158.3 335.5±134.4 354.0±151.8 327.3±149.3 331.3±130.4 328.9±104.6 0.070 0.059
Difference of CMT 
(μm)
−108.2±186.8 −87.8±213.6 −111.8±192.1 −102.1±198.9 −118.8±186.2 −109.8±183.5 −97.1±150.7 0.456 0.766
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 – –
95% CI (logMAR) −116.3 to −100.0 −124.9 to −50.7 −134.7 to −88.9 −122.7 to −81.5 −134.5 to −103.1 −126.5 to −93.1 −116.1 to −78.0 – –
Data were presented as mean value ±SD.
ANOVA, analysis of variance; BCVA, best corrected visual acuity; CMT, central macular thickness.
Figure 1 (A) Alterations of averaged baseline best corrected visual acuity (BCVA) (black square) and final BCVA (white square) according to the 
2- year term by starting year to final year. (B) Alteration of improvement of BCVA according to the 2- year term (black circle). Each vertical bar indicates 
SD of the mean. Each asterisk indicates statistically significant difference between baseline and final BCVA in each term.
significance. Analyses were performed with SAS V.9.4 TS1M5 
(SAS Institute) and were carried out by an independent biostatis-
tics data centre (STATZ Institute, Tokyo, Japan).
resulTs
Patient characteristics classified by 2- year observation period are 
listed in table 1. It is noteworthy that proportions of history of 
cataract surgery and photocoagulation outside the macula were 
higher in term 2010–2012 than the other periods (p<0.001 by 
ANOVA), and tended to decrease each year (p<0.001 by trend 
test).
Visual and anatomical outcome for 2- year period in each term 
are listed in table 2. There were significant tendencies to be 
better by year about both baseline BCVA (p=0.002 by trend test; 
figure 1A filled square) and final BCVA (p<0.001 by trend test; 
figure 1A open square). Furthermore, averaged improvement 
of BCVA also showed tendency to be better by year (p<0.001 
by trend test; figure 1B). Interestingly, baseline BCVA in term 
2011–2013 was worse than the other term, and improvement of 
BCVA in this term showed relatively good. While CMT in each 
starting year group showed statistically significant reduction, 
however there were no significant tendencies of baseline, final 
and difference of CMT by year.
Proportions of ‘improved’ eyes which gained >0.3 logMAR 
for 2 years were slightly increased by year (p=0.02 by trend 
test; figure 2A filled rhombus), in contrast to those of worsened 
eyes which lost >0.3 logMAR showed tendency to decrease 
(p<0.001 by trend test; figure 2A open rhombus). Proportions 
of eyes which maintained ‘good’ final BCVA >20/40 were grad-
ually increased by year (p<0.001 by trend test; figure 2B).
Treatment patterns and averaged frequency of each treat-
ment for 2 years were listed in table 3. Proportion of eyes which 
received anti- VEGF therapy was increased by year (p<0.001 
by trend test), but that received corticosteroid was not changed 
by year (p=0.137 by trend test) while proportions of eyes 
which received macular photocoagulation and vitrectomy were 
decreased by year (p<0.001 by trend test; figure 3).
Proportion of eyes which received IVB in anti- VEGF therapy 
was dramatically decreased (p<0.001 by trend test), in contrast 
to those which received IVR and IVA were increased by year 
(p<0.001 by trend test; figure 4A).
Proportions of eyes which received IVTA and STTA did not 
affect by year (p=0.446, p=0.094 by trend test). Regardless of 
the observational term, STTA was conducted in most cases of 
local corticosteroid therapy (figure 4B).
Averaged required number of each intervention for 2 years in each 
term was listed in table 3. Required number of anti- VEGF agents 
were dramatically increased by year (p<0.001 by trend test), in 
contrast to those of corticosteroid, macular photocoagulation and 
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Figure 2 (A) Alterations of proportions of eyes with >15 letters gaining from baseline (black rhombus: %) and proportions of eyes with >15 letters 
worsening from baseline (white rhombus: %). (B) Alteration of proportions of eyes having ‘good’ final best corrected visual acuity >20/40 (black 
hexagon: %).
Table 3 Treatment frequency and its number of eyes
















































































































































Number of times 1.1±0.3 1.1±0.3 1.1±0.3 1.1±0.2 1.0±0.2 1.0±0.2 1.1±0.2 0.558 0.221
Data about number of times were presented as mean value ±SD.
ANOVA, analysis of variance; PC, photocoagulation; TA, triamcinolone acetonide; VEGF, vascular endothelial growth factor.
trend test; figure 5A). As to anti- VEGF agents, required number of 
IVB was 2–3 times regardless of starting year, in contrast, those of 
IVR and IVA simply increased by year (figure 5B).
dIsCussIon
According to results of this study, treatment patterns for DMO were 
found to have been changed in recent years; proportion of eyes 
which received anti- VEGF therapy has been increased, in contrast 
to those received macular photocoagulation and vitrectomy has 
been decreased by year. Improvement of BCVA for 2 years of inter-
vention to DMO was gradually better, and the percentage of eyes 
with final BCVA better than 20/40 were also gradually higher by 
year. In contrast, anatomical regression of CMT was not influenced 
by treatment pattern and starting year of intervention. Previous 
study results suggested that CMT cannot substitute reliably as a 
surrogate for visual acuity.19 In this study, although it should be 
handled carefully because each CMT was measured with different 
instrument, anatomical regression of DMO was also found not to 
be related to functional improvement.
Alterations of visual prognosis by year
According to our study results, improvement of BCVA for 2 years 
after the initial intervention in each term tended to be better 
by year. Considering the fact that both baseline and final BCVA 
showed tendency to be better by year, improvement of BCVA 
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Figure 3 Alterations of proportions of eyes which received 
antivascular endothelial growth factor agents (black circle), local 
corticosteroids (white square), macular photocoagulation (black 
triangle) and vitrectomy (white rhombus).
Figure 4 (A) Alterations of proportions of eyes which received bevacizumab (black circle), ranibizumab (white circle) or aflibercept (grey circle) to 
eyes which received antivascular endothelial growth factor agents. (B) Alterations of proportions of eyes which received as intravitreal (black square) 
or subtenon (white square) injection to eyes which received local corticosteroids.
for DMO, indicating that the treatment options by retina special-
ists have become effective by year. Although it remains unclear 
the reason why the term of 2011–2013 alone is out of this trend, 
baseline BCVA in this term was statistically worse than in the 
other term; therefore, it is likely to be caused by a ceiling effect 
(eyes with good BCVA at baseline had less vision to gain to return 
to normal vision, making very large improvements impossible).20
In this study, averaged baseline BCVA of 0.44 (0.40–0.51) 
logMAR which is converted to 63 (59–65) letters was almost the 
same as those in previous clinical trials, whose averaged baseline 
BCVA was 62.4–64.8 letters in RESTORE study, 58.8–60.8 letters 
in VIVID/VISTA studies.11 Even a latest improvement of BCVA in 
this study which was −0.13 logMAR (+6.5 letters) did not reach 
to clinical trials of +6.7–7.9 letters,12 or +11.1–11.5 letters.11 In 
these clinical trials, averaged number of anti- VEGF drug injection 
for 2 years was 14.5–15.2 times,12 or 13.5–22.6 times,11 while the 
latest averaged injection number in our study was 5.5 times, and 
26.6% of DMO eyes did not receive anti- VEGF therapy.
The proportion of worsened eyes decreased by year, while 
those of improved eyes did not change much. The yearly alter-
ations of treatment patterns seem to have rescued the worsened 
eyes. In the latest term of 2015–2017, there were 27.0% of 
improved and 9.4% of worsened eyes, which is still less than the 
previous reports in RESTORE study12 (≈25.0% of improved, 
and ≈1% of worsened eyes), or in VIVID/VISTA studies11 
(≈35.0% of improved, and ≈2% of worsened eyes). More 
proportions and more injection number of anti- VEGF agents 
may lead suppression of worsened eyes.
Treating DMO eyes according to regularly administration 
of anti- VEGF agents probably produce the best possible visual 
prognosis, but treatment is expensive and compliance is diffi-
cult to maintain. Our real- world data indicated that there still 
remained room to devise treatment options for DMO.
The optimal goal of treatment for DMO is to achieve good 
visual acuity of 20/40 or more after any interventions.21 
According to the other real- world study of anti- VEGF treat-
ment for DMO results, 51.9%–62.3% patients achieved 
>20/40 BCVA.22 In our study, the proportion of eyes which 
maintained final >20/40 BCVA is increased and reached to 
59.0% in the latest term of 2015–2017. Even in this period, 
26.6% of eyes did not receive anti- VEGF agents during the 
clinical course.
Alterations of treatment patterns by year
According to our data set, treatment patterns for DMO were 
changed by year. Especially, in the term of 2014–2016, and 
2015–2017, proportion of anti- VEGF therapy was dramatically 
increased. In Japan, ranibizumab, a humanised anti- VEGF mono-
clonal antibody Fab fragment that binds to VEGF- A,10 and afliber-
cept, a fusion glycoprotein consisting of the extracellular domain 
of VEGF receptors 1 and 2 fused to the Fc domain of human IgG1 
that binds to VEGF- A, VEGF- B and placental growth factor11 
was approved in February and November 2014. Thus, in the last 
two terms, retina specialists must not hesitate to apply anti- VEGF 
agents.
While, corticosteroid therapy which is usually applied as 
STTA regardless of the starting year in Japan had been applied 
to half of DMO eyes. In contrast, macular photocoagulation and 
vitrectomy tended to reduce each year. These interventions were 
likely to have been replaced by anti- VEGF therapy.
Recently, anti- VEGF therapy is recommended as the first- line 
therapy for centre involving DMO, which is a leading cause of 
vision impairment,23 24 while not a few patients were found 
to be inconsistent or non- responsive to anti- VEGF agents25 26 
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Figure 5 (A) Alterations of averaged required number of interventions for 2 years, which was antivascular endothelial growth factor (VEGF) agents 
(black circle), local corticosteroids (white square), macular photocoagulation (black triangle) and vitrectomy (white rhombus). (B) Alterations of 
averaged required number of each anti- VEGF agent for 2 years, as bevacizumab (black circle), ranibizumab (white circle) and aflibercept (grey circle). 
Note that ranibizumab and aflibercept had been approved since 2014; thus, these data on first two terms were omitted.
therapy. As a second- line therapy, corticosteroid is considered 
to be effective for chronic DMO,27 and macular photocoag-
ulation is agreed as an excellent treatment for centre threat-
ening DMO with good vision.4 Vitrectomy may be expected 
as alternative therapy for persistent DMO which resisted to 
the other therapies despite that the efficacy of vitrectomy for 
DMO remains uncertain.28
Before 2014 in the absence of approved anti- VEGF agents, 
bevacizumab, an off- labelled, humanised anti- VEGF mono-
clonal antibody29 was widely used with fewer (1.8–2.9) injec-
tions. Among large prospective clinical trials that evaluated the 
efficacy and safety of ranibizumab and bevacizumab treatment 
in patients with DMO, the largest gains in BCVA were seen 
in trials that used the most frequent (monthly) administration 
of anti- VEGF. These results suggest a correlation between 
the frequency of anti- VEGF injections and efficacy.30 Annual 
increase of frequency of anti- VEGF injections may be involved 
in better visual prognosis, and in the latest periods, retina 
specialists in Japan positively tended to use ranibizumab and 
aflibercept with a greater number of injections. In contrast, 
treatment frequency of other therapies was less than two times 
per 2 years and did not change by treatment term. Thus, both 
proportions of anti- VEGF therapy and its frequency were 
increased by year and cause better 2- year visual prognosis for 
DMO. More recently, comparison of efficacy for visual prog-
nosis among aflibercept, ranibizumab and bevacizumab was 
investigated, and superiority of aflibercept for DMO eyes with 
worse baseline BCVA was reported.31 32 In this study, increased 
proportion and frequency of aflibercept by year may also have 
contributed to better 2- year visual prognosis for DMO.
Different form randomised controlled trials which assess the 
effectivity of certain treatment interventions under controlled 
conditions, real- world studies provide information on the 
clinical results under real- world conditions. To conduct real- 
world studies, data collection must be cared, however were 
usually performed automatically from electronic medical 
records21 33 or extracted from public healthcare systems.34 35 
In our STREAT- DMO database, apart from these previous 
retrospective studies, submitted data from each institution 
were collected in the statistics centre, and manually checked 
and carefully reviewed one by one by numerous investigators. 
Also in our database, clinical course in each eye was limited to 
2 years; thus, it was possible to compare the visual prognosis 
among starting year of intervention. Although real- world data 
have numerous limitations, results can be better generalised 
to typical clinical practice.36 According to our study results, 
application of anti- VEGF therapy to treatment- naïve DMO 
eyes and its frequency has been increased year by year; as a 
result, visual prognosis, especially as decreasing worsened 
eyes, has been better in Japan. In future, mimic study should 
be required to compare with our current yearly information.
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